Asset Details
Do you wish to reserve the book?
Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia
Do you wish to request the book?
Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Non-seminomatous mediastinal germ cell tumor and acute megakaryoblastic leukemia
2017
Overview
The association between mediastinal germ cell tumors (MGCT) and acute megakaryoblastic (M7) leukemia has been known for many years. We hereby present this review to better characterize the coexistence of these entities as well as the salient features, the treatment options, and the overall prognosis. A search of PUBMED, Medline, and EMBASE databases via OVID engine for primary articles and case reports under keywords “germ cell tumors” and “acute myeloid leukemia” revealed a total of 26 cases in English that reported MGCT and M7 leukemia. The median age at diagnosis of MGCT was 24 (13–36) years. All cases were stage III. All cases of MGCT were of non-seminomatous origin and one case was unclassified. MGCT occurred prior to the diagnosis of leukemia in 46% of cases and concomitantly in 31% of cases. M7 leukemia was never reported prior to the appearance of MGCT. Complex cytogenetics and hyperdiploidy were the most commonly reported cytogenetic abnormalities. In the 23 cases where the treatment regimen was available, platinum-based chemotherapy directed towards management of the germ cell tumors was used initially in 21 cases and leukemia-directed treatment was used initially in 2 cases only. The median time from diagnosis of MGCT to development of M7 leukemia was 5 (2.25–39) months. Median time to death from the initial diagnosis of MGCT was 6 (0.5–60) months. Patients with a history of MGCT are at higher risk of developing M7 leukemia. They need long-term follow-up with a particular attention to the development of hematological malignancies. The overall prognosis remains poor.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Female
/ Humans
/ Leukemia
/ Leukemia, Megakaryoblastic, Acute - diagnosis
/ Leukemia, Megakaryoblastic, Acute - drug therapy
/ Leukemia, Megakaryoblastic, Acute - genetics
/ Leukemia, Megakaryoblastic, Acute - mortality
/ Male
/ Mediastinal Neoplasms - diagnosis
/ Mediastinal Neoplasms - drug therapy
/ Mediastinal Neoplasms - genetics
/ Mediastinal Neoplasms - mortality
/ Medicine
/ Neoplasms, Germ Cell and Embryonal - diagnosis
/ Neoplasms, Germ Cell and Embryonal - drug therapy
/ Neoplasms, Germ Cell and Embryonal - genetics
/ Neoplasms, Germ Cell and Embryonal - mortality
/ Oncology
/ Ploidies
/ Tumors
